75 results about "Senile macular degeneration" patented technology

An opthalmic spectacle or contact sharp cut-on orange lens that improves visual acuity and substantially reduces eye damage in a bright sunlit environment. The lenses substantially eliminate ultraviolet radiation and blue light shorter than .[.515.]. .Iadd.520 .Iaddend.nm. The ultraviolet radiation has been implicated as a cause of cateractogenisis. The blue light is implicated in senile macular degenerations, night blindness and snow blindness. The lens is substantially transparent to wavelengths greater than .[.636.]. .Iadd.600 .Iaddend.nm which are most useful for high visual acuity in bright sunlit environment.

The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.

The invention discloses an eyesight improving lutein capsule comprising the following raw materials in parts by weight: 20-30 parts of zinc gluconate, 10-14 parts of lutein, 0.2-0.8 part of vitamin A, 10-14 parts of vitamin C, 2-4 parts of vitamin E, 140-160 parts of soybean oil and 5-15 parts of bee wax. The eyesight improving lutein capsule disclosed by the invention is rich in nutrition and good in taste, and not only has the effects of relieving visual fatigue and improving eyesight, but also has the effects of preventing dry eye syndrome, myopia, age-related macular degeneration and the like.

The invention provides a kit for detecting senile macular degeneration disease, comprising a related reagent selected freely from rs1061170 variation of exon 9, rs1329428 variation of intron 15, rs800292 variation of exon 2 used for detecting CFH gene and/or rs3753394 variation in a 5' non-coding region used for AMD screening diagnosis. By detecting whether the above locus has variation or not, the kit can detect that risk of senile macular degeneration disease has high association with AMD, and can be used for monitoring and detecting AMD high risk group at an early stage so as to implement early-stage prevention and curing and reduce vision damage to AMD high risk group.

The invention relates to the technical field of artificial intelligence, and provides a fundus image recognition method and device, fundus image recognition equipment and a storage medium. The methodcomprises: obtaining an fundus image; extracting first target data from the fundus image, and performing redundancy elimination processing on the first target data to obtain a first central concave feature; generating a macular area mask according to the first central concave feature; intercepting a macular area in the fundus image through a macular area mask to obtain a macular area image; and identifying senile macular degeneration lesion features in the macular area image, and classifying the macular area image according to the senile macular degeneration lesion features. The macular area image is cut from the fundus image through the mask generation model, the macular area image is classified according to AMD focus features in the macular area image, feature data in the macular area image is obvious and easy to recognize, and therefore the classification accuracy of the fundus image is effectively improved.

The present invention belongs to the field of biomedicine, and relates to a nanometer fiber polymer composite membrane, a preparation method and uses thereof. According to the nanometer fiber polymer composite membrane, the low layer is a hydrogel nanometer fiber membrane, the middle layer is a Matrigel matrix gel layer, and the upper layer is a retinal pigment epithelium layer. The nanometer fiber polymer composite membrane can be adopted as a bio-scaffold for supporting growth and transplantation of RPE cells, and has characteristics of softness, elasticity, good permeability, biodegradability and a structure similar to extracellular matrix, wherein adhesion and differentiation of the RPE monolayer cells and surgical procedure operations are easily achieved with the characteristics, and the nanometer fiber polymer composite membrane can be discharged out of a body through a metabolism process after transplantation so as not to generate harm to the human body. According to the present invention, a bio-nanometer material and cell engineering are combined, brightness and hope are provided for age-related macular degeneration (ARMD) patients with the successful research, and great economic benefits and social benefits are generated.

The current situation is such that it is difficult for drugs to reach posterior tissues of an eyeball, such as choroid and retina, with the result that treating diseases in such regions is difficult. Thus, how to attain effective delivery of drugs is of importance. It has been found that effective delivery of drugs to positerior tissues of the eyeball, such as choroid and retina, especially those wherein vascularization has occurred can be accomplished by systemic administration, especially intravenous administration of polymer micells having a drug incorporated therein. Further, it has been found that when a photosensitive substance is used as a drug and PDT is carried out, choroidal neo-vessels can be effectively choked so as to be useful for the treatment of age-related macular degeneration.

The present invention is the application of hypocrellin photosensitizer in pharmacy. Hypocrellin photosensitizer is used in preparing photodynamic medicine for treating nevus flammeus, senile macular degeneration and other blood capillary diseases.The said hypocrellin includes hypocrellin A, hypocrellin B and medicinal carrier. The present invention utilizes the photophysical and chemical features of hypocrellin photosensitizer, especially its maximum absorption spectrum value at 450-580 nm wavelength range, the light of which has effective penetrating depth of 1-2 mm to provide new clinicalindications for the hypocrellin.

The invention discloses an asthenopia-alleviating troche which comprises the following components in percentage by mass: 5-30% of semen cassia extract, 5-20% of lycium ruthenicum, 1-12% of lutein esters, 1-10% of dunaliella salina, 5-20% of blackcurrant extract, 5-20% of grape seed extract and the balance of auxiliary materials. The asthenopia-alleviating troche provided by the invention can effectively protect eyesight, alleviate asthenopia and prevent senile macular degeneration. Retina macular degeneration is improved by lutein esters, asthenopia and black eyes are alleviated by adding anthocyanin, and visual purple synthesis is promoted by adding beta-carotene, so that the eyesight is protected in many aspects. The invention also provides a preparation method of the asthenopia-alleviating troche.

The invention belongs to the technical field of edible blend oil, and particularly relates to edible blend oil containing lutein ester and a preparation method thereof. The edible blend oil containinglutein ester comprises the following components in percentage by mass: 83.7-93.5% of edible vegetable oil, 0.1-3.5% of lutein ester, 0.2-1.2% of carotene, 1.2-3.6% of antioxidant and 5-8% of composite unsaturated fatty acid. The edible blend oil containing lutein ester can obviously enhance the visual ability, increase the blood flow of the eyeballs and improve the eye muscle fatigue, thereby lowering the morbidity of cataract, senile macular degeneration and juvenile myopia. The edible blend oil containing lutein ester has the effects of resisting oxidation, lowering the cholesterol and thelike.

The invention relates to the technical field of medicines, and concretely relates to a novel dihydroporphine photosensitizer - purpurin-18 ether derivative, a preparation method thereof, and a use of the purpurin-18 ether derivative in the preparation of antitumor medicines. The chemical structure of the purpurin-18 ether derivative is represented by general formula (I) shown in the description. The purpurin-18 ether derivative has the advantages of high efficiency and low toxicity, and can be used for preparing new photodynamic therapy medicines of cancers, photodynamic therapy medicines of benign diseases, such as senile macula lutea denaturation and nevus flammeus, and photodynamic therapy medicines of condyloma acuminatum.

Provided are VEGF and PDGFRβ bispecific fusion protein and application thereof. More specifically, a bifunctional fusion protein comprising VEGFR extracellular ligand binding domain and PDGFRβ antibody fragment is provided, which can be used to treat wet age-related macular degeneration (AMD) and any other diseases that can be improved by inhibiting VEGF and PDGF signaling pathways , such as tumors and diabetic retinopathy.

The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.

It is intended to provide a pharmaceutical product with a high therapeutic effect in the treatment of a retinal disease accompanied by angiogenesis such as age-related macular degeneration or diabetic retinopathy. A therapeutic agent for a retinal disease containing a substance that specifically inhibits the expression of HIF-1alpha and a substance that specifically inhibits the expression of HIF-2alpha. The inhibitor which is an active ingredient of the therapeutic agent of the invention is an RNAi-inducible nucleic acid, an antisense nucleic acid, or a ribozyme against HIF-1a and HIF-2a, or an expression vector therefor.

This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula I

or a pharmaceutically acceptable salt thereof, wherein R¹, L¹, L², V, L³, and R² are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

The invention discloses a near-infrared fundus therapeutic instrument, and relates to the technical field of medical instruments for eye diseases. The near-infrared fundus therapeutic instrument comprises a head-mounted main body and a controller, wherein the head-mounted main body is provided with a near-infrared light source electrically connected with the controller, the near-infrared light source is used for irradiating the fundus of a tested user, the near-infrared light source has a plurality of preset light emitting powers, and the controller is used for controlling the near-infrared light source to select the corresponding preset light emitting power so as to adapt to the fundus disease condition of the tested user. The near-infrared fundus therapeutic instrument can conveniently and effectively assist in treating fundus diseases such as central serous retinitis, senile macular degeneration, and the like.

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.